FDA Refund |
12 Months Ended |
---|---|
Sep. 30, 2019 | |
Receivables [Abstract] | |
FDA REFUND |
9. FDA REFUND
On August 29, 2018, the Company received notification from the Food and Drug Administration ("FDA") that the Company was being refunded $818,343 of 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA's review of the associated applications. The Company recorded the $818,343 receivable as other income during the year ended September 30, 2018 and received the refund on October 1, 2018. |
X | ||||||||||
- Definition The entire disclosure for financing receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|